Skip to main content

Advertisement

Table 2 Comparison of clinical outcomes between the two groups

From: Impact of switching from intravenous to oral linezolid therapy in Japanese patients: a retrospective cohort study

  Intravenous to oral therapy group
(n = 21)
Intravenous therapy group
(n = 52)
p-value
Duration of linezolid treatment (days) 12 ± 5.8 14 ± 5.6 0.22
Reduction in level of CRP from baseline of ≥30 % (n [%]) 16 (76.2) 38 (73.1) 0.78
Reduction in platelet count from baseline of ≥30 % (n [%]) 7 (33.3) 20 (38.5) 0.68
Re-administration of an anti-MRSA agent <90 days after hospital discharge (n [%]) 2 (9.5) 7 (13.5) 0.64
Death <28 days after hospital discharge (n [%]) 3 (14.3) 10 (19.2) 0.62
Drug costs (/day/person) US$222 US$305 <0.001
  1. MRSA, methicillin-resistant Staphylococcus aureus; data are the mean ± standard deviation
  2. P-values were calculated based on Students t-test or Welch’s t-test for continuous variables and chi-squared analysis for discrete variables